Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
2024-01-31 16:24:30 ET More on Viking Therapeutics Biotech And Pharma Diversification Pays Off Viking: Results From 2 Clinical Trials Of Weight Loss Drug Ahead, Other Catalysts On Tap Barron’s cites cancer and weight loss plays for biotech M&A Viki...
2024-01-30 10:22:11 ET More on Arcus Biosciences Arcus Biosciences: Showing There Might Be Something To TIGIT After All Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey Arcus Biosciences, Inc. (RCUS) Q3 2023 Earnings Call Transcript Gilead invest...
2024-01-29 10:43:48 ET More on HOOKIPA Pharma Hookipa Pharma stock soars on $21.25M equity investment from Gilead HOOKIPA Pharma GAAP EPS of -$0.17 beats by $0.03, revenue of $6.87M beats by $2.62M Seeking Alpha’s Quant Rating on HOOKIPA Pharma Histori...
2024-01-26 12:47:12 ET Summary Today, we take another look at Halozyme Therapeutics, Inc., which enhances drug delivery through its ENHANZE platform, earning royalties and milestone payouts from major drugmakers. Management has plans in place to more than double royalty revenues b...
2024-01-26 07:16:34 ET More on Cigna, CVS Health, etc. Humana: The $300 Level Could Get Taken Out In The Near Future Humana Inc. (HUM) Q4 2023 Earnings Call Transcript CVS Health: Back In The Buy Column Humana gets downgrade at Deutsche Bank as stock nears fo...
– Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision – – Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apart – – Detailed results from two glo...
2024-01-22 08:52:21 ET More on AC Immune AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts AC Immune issues updates on Phase 2 studies, cash runway AC Immune Alzheimer's drug advanced into Phase 2b testing Seeking Alpha’s Quant Rating o...
2024-01-19 07:29:39 ET More on Coherus BioSciences Coherus BioSciences: FDA Approvals Spice Up The Pipeline Coherus BioSciences Is A Buy On The Dip After Toripalimib Approval Coherus: The Surface Acquisition Is A Distraction Coherus ends Junshi-partnered TIGI...
2024-01-16 12:40:46 ET More on Halozyme Therapeutics Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Call Transcript Halozyme Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation ...
2024-01-14 12:00:24 ET More on CRISPR, GSK, etc. Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) ...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
– Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) – – Safety data were consistent with the known safety profile for Susvimo in people...